Navepegritide Patent Expiration
Navepegritide was first introduced by Ascendis Pharma Growth Disorders As
Navepegritide Patents
Given below is the list of patents protecting Navepegritide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Yuviwel | US12377133 | Dry Pharmaceutical Formulations Of Cnp Conjugates | Nov 12, 2042 | Ascendis |
| Yuviwel | US10835578 | Cnp Prodrugs With Large Carrier Moieties | Jan 05, 2037 | Ascendis |
| Yuviwel | US11154593 | Cnp Prodrugs With Large Carrier Moieties | Jan 05, 2037 | Ascendis |
| Yuviwel | US11224661 | Controlled-Release Cnp Agonists With Increased Nep Stability | Jan 05, 2037 | Ascendis |
| Yuviwel | US11311604 | Controlled-Release Cnp Agonists With Low Npr-C Binding | Jan 05, 2037 | Ascendis |
| Yuviwel | US11389510 | Controlled-Release Cnp Agonists With Low Initial Npr-B Activity | Jan 05, 2037 | Ascendis |
| Yuviwel | US11389511 | Controlled-Release Cnp Agonists With Reduced Side-Effects | Jan 05, 2037 | Ascendis |
| Yuviwel | US11413351 | Cnp Prodrugs With Carrier Attachment At The Ring Moiety | Jan 05, 2037 | Ascendis |
| Yuviwel | US12083182 | Controlled-Release Cnp Agonists With Increased Nep Stability | Jan 05, 2037 | Ascendis |
| Yuviwel | US12156917 | Cnp Prodrugs With Carrier Attachment At The Ring Moiety | Jan 05, 2037 | Ascendis |
| Yuviwel | US12239689 | Controlled-Release Cnp Agonists With Low Initial Npr-B Activity | Jan 05, 2037 | Ascendis |
| Yuviwel | US8906847 | Prodrug comprising a drug linker conjugate | Apr 30, 2031 | Ascendis |
Navepegritide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Navepegritide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia | Ascendis Pharma A/S | NA |
COMPLETED
(Jun 1, 2026)
| PHASE2 |
| A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia | Ascendis Pharma Growth Disorders A/S | NA |
COMPLETED
(Jun 1, 2026)
| PHASE2, PHASE3 |
| A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia | Ascendis Pharma A/S | NA |
RECRUITING
(Apr 1, 2026)
| PHASE2 |
| A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia. | Ascendis Pharma A/S | NA |
RECRUITING
(Apr 1, 2026)
| PHASE2 |